SCHEMBL3227670

SCHEMBL3227670

[2H]C([2H])([2H])C(c1ccc(S(=O)(=O)Cl)cc1)(C([2H])([2H])[2H])C([2H])([2H])[2H]

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.45
TDP1 Q9NUW8 3/20 0.43
HSD17B10 Q99714 2/20 0.43
HTT P42858 3/20 0.41
NPSR1 Q6W5P4 2/20 0.41
USP2 O75604 1/20 0.41
ALOX15 P16050 1/20 0.41
HSD11B1 P28845 1/20 0.41
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
LMNA P02545 3/20 0.37
GAA P10253 1/20 0.37
HPGD P15428 3/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
TSHR P16473 2/20 0.37
BCHE P06276 1/20 0.37
ACHE P22303 1/20 0.37
MAPT P10636 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL66108 0.85 ALDH1A1 (0.61) ALDH1A1TDP1HSD17B10HTTNPSR1
SCHEMBL31190811 0.80 ALDH1A1 (0.40) ALDH1A1TDP1HSD17B10HTTNPSR1
SCHEMBL3219450 0.79 CA2 (0.54) ALDH1A1TDP1NPSR1USP2MEN1
SCHEMBL17897408 0.79 ALDH1A1 (0.55) ALDH1A1TDP1HSD17B10HTTNPSR1
SCHEMBL14026730 0.78 ALDH1A1 (0.32) ALDH1A1TDP1HSD17B10
SCHEMBL3041567 0.76 ALDH1A1 (0.48) ALDH1A1TDP1HSD17B10HTTHSD11B1
SCHEMBL14533597 0.75 ALDH1A1 (0.50) ALDH1A1TDP1HSD17B10HTTNPSR1
SCHEMBL27685431 0.74 ALDH1A1 (0.46) ALDH1A1TDP1HSD17B10HTTNPSR1
SCHEMBL651902 0.74 ALDH1A1 (0.71) ALDH1A1TDP1HSD17B10USP2LMNA
SCHEMBL11521879 0.73 ALDH1A1 (0.50) ALDH1A1TDP1HSD17B10HTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606522-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives ORSOBIO, INC. (US) 2026-04-21 US disclosed
US-20240409508-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES ORSOBIO, INC. 2024-12-12 US disclosed
US-12049439-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives ORSOBIO, INC. (US) 2024-07-30 US disclosed
EP-3796975-B1 SULFONYLAMINOBENZAMIDE DERIVATIVES ORSOBIO INC (US) 2023-08-30 EP disclosed
US-20220055985-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES GILEAD SCIENCES, INC. 2022-02-24 US disclosed
US-11136290-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives THE LIVER COMPANY INC. (US) 2021-10-05 US disclosed
US-8080549-B2 Endothelin receptor antagonists CONCERT PHARMACEUTICALS, INC. (US) 2011-12-20 US disclosed
US-20100063076-A1 Endothelin receptor antagonists SUN PHARMACEUTICAL INDUSTRIES, INC. 2010-03-11 US disclosed
US-20100063076-A1 Endothelin receptor antagonists SUN PHARMACEUTICAL INDUSTRIES, INC. 2010-03-11 US disclosed
US-20090005394-A1 Endothelin receptor antagonists SUN PHARMACEUTICAL INDUSTRIES, INC. 2009-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220055985-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES STS, SULT2A1, SCN2B ALDH1A1 245/4885TDP1 4606/4885HSD17B10 1023/4885
US-12049439-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives STS, SULT2A1, SCN2B ALDH1A1 245/4885TDP1 4606/4885HSD17B10 1023/4885
US-20100063076-A1 Endothelin receptor antagonists EDNRA, EDNRB, ECE1 ALDH1A1 3474/4885TDP1 2153/4885HSD17B10 2449/4885
US-12606522-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives NR3C2, NR5A1, SRD5A2 ALDH1A1 1507/4885TDP1 4292/4885HSD17B10 69/4885
US-20240409508-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES STS, SULT2A1, SCN2B ALDH1A1 245/4885TDP1 4606/4885HSD17B10 1023/4885
US-11136290-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives STS, SULT2A1, SCN2B ALDH1A1 245/4885TDP1 4606/4885HSD17B10 1023/4885
US-20090005394-A1 Endothelin receptor antagonists EDNRA, EDNRB, ECE1 ALDH1A1 3953/4885TDP1 1468/4885HSD17B10 2391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.